Trinity Biotech (TRIB) Revenue (2009 - 2024)

Trinity Biotech has disclosed Revenue across 16 years of filings, most recently posting $15.9 million for Q4 2024.

• In Q4 2024, Revenue rose 18.09% year-over-year to $15.9 million; the TTM figure through Dec 2024 stood at $61.6 million (up 8.31% YoY), while the FY2025 annual figure was $43.8 million, down 28.87% from the prior year.
• Revenue came in at $15.9 million for Q4 2024 at Trinity Biotech, up from $15.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $32.8 million in Q4 2020 to a low of $13.4 million in Q4 2023.
• Average Revenue over 5 years is $18.8 million, with a median of $15.8 million recorded in 2022.
• The largest YoY upside for Revenue was 61.28% in 2021 against a maximum downside of 40.41% in 2021.
• Over 5 years, Revenue stood at $32.8 million in 2020, then tumbled by 40.41% to $19.5 million in 2021, then retreated by 19.46% to $15.7 million in 2022, then fell by 14.61% to $13.4 million in 2023, then gained by 18.09% to $15.9 million in 2024.
• Per Business Quant data, the three most recent Revenue figures were $15.9 million in Q4 2024, $15.2 million in Q3 2024, and $15.8 million in Q2 2024.